Adarx Pharmaceuticals, A Leader In Next Generation Rna Therapeutics, Announces Oversubscribed $200 Million Series C Financing

Aug 09, 2023•over 2 years ago

Amount Raised

$200 Million

Round Type

series c

San Diego

Investors

Sr One Capital ManagementOrbi MedLilly Asia VenturesAscenta CapitalVivo CapitalVenrock Healthcare Capital PartnersT. Rowe Price Associates Inc.Redmile GroupMarshall WaceInvusHbm Healthcare InvestmentsCormorant Asset ManagementCommodore CapitalBlackrockTcgxBain Capital Life Sciences

Description

ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing. The financing was led jointly by Bain Capital Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates Inc., Venrock Healthcare Capital Partners, and Vivo Capital

Company Information

Company

ADARx Pharmaceuticals, Inc.

Location

5871 OBERLIN DRIVE, SUITE 200

San Diego, California, United States

About

ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease. We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends